The frequent loss or mutation of TP53, RB1, and PTEN tumor suppressor genes in CRPC could make cancer cells dependent on the G2/M checkpoint for survival, increasing their sensitivity to G2/M checkpoint targeted agents [3]. This evidence concerns the gene RB1 and cancer.